Perkin78,
This is a post I made on August 11, 2014.
The only statement, I believe that is incorrect is that INO did not have the funding to do the phase III, trial, but I believe they have a shelf registration in place that could fund such a trial or they could raise additional funds for that purpose.
From August 11, 2014
I believe investors might have been looking for the release of additional clinical information and/or information regarding a partnership to develop VGX-3100.
Dr. Kim only mentioned partnership in passing at the end of the presentation, but reaffirmed that INO has the funding to do the phase 3 trial on their own. Are his statements part of a negotiation strategy or:
The following was taken from my post after the phase 2 data:
Dr. Kim has made no secret that his primary focus is getting VGX-3100 into a phase 3 trial and I think he has a preference to run the trial without a partner. He wants to retain complete control. I believe doing the clinical trial without a partner brings undo risk to INO and the stock. Even the very largest pharma companies often partner to reduce the risk of phase 3 trials and potential market approval.
Still long, but hoping Dr. Kim and the board make the best decision with regard to partnering.
News 
Market Data 
Discover 
